Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6696449 | 7371455 | I | 6696449-7 | 20100317 | 20100406 | 20100421 | EXP | TUK2010A00051 | TAKEDA PHARMACEUTICALS NORTH AMERICA. | 54 | YR | M | N | 20100420 | UNITED KINGDOM |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6696449 | 1013567108 | PS | ACTOS | 1 | ORAL | 15 MG (15 MG), ORAL | N | 21073 | |||
| 6696449 | 1013598212 | C | ASPIRIN | 1 | |||||||
| 6696449 | 1013598213 | C | ATORVASTATIN CALCIUM | 1 | |||||||
| 6696449 | 1013598214 | C | GLUCOPHAGE SR (METFORMIN HYDROCHLORIDE) | 2 | |||||||
| 6696449 | 1013598215 | C | TRBESARTAN (IRBESARTAN) | 2 | |||||||
| 6696449 | 1013598216 | C | ACETAMINOPHEN | 1 | |||||||
| 6696449 | 1013598218 | C | SITAGLIPTIN | 2 | |||||||
| 6696449 | 1013598219 | C | TADALAFIL (TADALAFIL) | 2 |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 6696449 | 1013567108 | DIABETES MELLITUS |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 6696449 | DS |
Reactions reported
| Event ID | PT |
|---|---|
| 6696449 | ARTHRALGIA |
| 6696449 | DEAFNESS UNILATERAL |
| 6696449 | EYELID OEDEMA |
| 6696449 | FATIGUE |
| 6696449 | HEADACHE |
| 6696449 | TINNITUS |
| 6696449 | VERTIGO |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 6696449 | FGN |
| 6696449 | HP |
| 6696449 | OTH |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 6696449 | 1013567108 | 20100317 | 20100319 | 2 | DAY |